Status:
COMPLETED
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
Lead Sponsor:
University of Colorado, Denver
Conditions:
Differentiated Thyroid Cancer
Eligibility:
All Genders
21+ years
Phase:
PHASE1
Brief Summary
The purpose of the study is to find out if the small dose of radioiodine, that is used for the dosimetry study on patients with differentiated thyroid cancer, may stun the cancer cells and make the th...
Detailed Description
This study plans to learn more about a medical problem called thyroid stunning. Thyroid stunning is a temporary decrease in the function of thyroid cells after small doses of radioiodine, a radioactiv...
Eligibility Criteria
Inclusion
- Patient must be 21-years-old or greater.
- Patient must be status post near total thyroidectomy for differentiated thyroid cancer without known distant metastases and who are planning to undergo routine remnant thyroid tissue ablation with I-131.
- Patients must qualify for thyroid ablation with I-131.
Exclusion
- Women who are pregnant or breastfeeding.
- Prior bovine TSH use.
- Known metastatic thyroid cancer.
- History of cardiovascular disease that may adversely affect patient participation at the discretion of the primary investigator.
- Patients on hemodialysis.
- Patients with acute serious illnesses at the discretion of the primary investigator.
Key Trial Info
Start Date :
November 30 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 20 2019
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT02278198
Start Date
November 30 2012
End Date
September 20 2019
Last Update
October 24 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fawn N White
Denver, Colorado, United States, 80211